Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Beta Erythropoietin in Low/Int-1 Risk MDS (SIMIDIS)
NCT00495547Phase 2Terminated
- Sponsor
- Fundación PETHEMA
- Start
- Feb 2009
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in myelodysplastic syndrome (MDS), sponsored by Fundación PETHEMA. Started Feb 2009; status: terminated.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00495547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00495547.